Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the cancer anorexia-cachexia syndrome (cacs) market grown in recent years?
The market size of the cancer anorexia-cachexia syndrome (CACS) has seen swift expansion in the past few years. It is projected to rise from $3.51 billion in 2024 to $3.89 billion in 2025, presenting a compound annual growth rate (CAGR) of 11.0%. This historical growth stems from factors such as increased cancer cases, heightened awareness amongst healthcare professionals, an enhanced emphasis on cancer patients’ quality of life, the establishment of more clinical trials, along with productive pharmaceutical collaborations and partnerships.
How is the cancer anorexia-cachexia syndrome (cacs) market size expected to evolve during the forecast period?
The market for cancer anorexia-cachexia syndrome (CACS) is projected to experience a sharp increase in its size in the coming years. The market is estimated to escalate to a value of $5.84 billion in 2029, with a compound annual growth rate (CAGR) of 10.7%. The predicted expansion during the forecast period is linked with higher cancer survival statistics, burgeoning investments in the supporting care for oncology, the evolution of personalized medicine, an amplified emphasis on multimodal therapies, and the development of healthcare infrastructure. Notable trends anticipated during the forecast period range from progress in palliative care, to the rise of targeted therapies, technological breakthroughs in drug dispensing systems, the incorporation of Artificial Intelligence in drug creation, and the advancement of personalized medicine.
Get your cancer anorexia-cachexia syndrome (cacs) market report here!
Which key drivers are propelling the cancer anorexia-cachexia syndrome (cacs) market’s growth?
The rising instances of cancer are anticipated to fuel the expansion of the cancer anorexia-cachexia syndrome market. Cancer, an umbrella term for a variety of diseases involving unregulated cell growth, is on the increase globally due to reasons such as an aging populace, changes in lifestyle, environmental exposures, enhanced detection techniques, increased consciousness, and specific genetically related infections and cancers. The severe weight loss and malnutrition typically associated with cancer patients are addressed by Cancer Anorexia-Cachexia Syndrome (CACS), enhancing their overall life quality and treatment results. For example, Macmillan Cancer Support, a UK-based charitable body, indicated in a report in August 2024 that over 3 million people in the UK had cancer, with predictions for this figure to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer is bolstering the cancer anorexia-cachexia syndrome market. The Influence of Rising Healthcare Expenditure on the Market
What are the market segments in the cancer anorexia-cachexia syndrome (cacs) industry?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp
Which leading companies are shaping the growth of the cancer anorexia-cachexia syndrome (cacs) market?
Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.
What key trends are currently impacting the cancer anorexia-cachexia syndrome (cacs) market’s development?
The primary players in the market for cancer anorexia-cachexia syndrome are concentrating their efforts on creating ground-breaking solutions like monoclonal antibody therapies. These remedies aim to improve therapy efficiency, augments patient health results, and fulfill currently unaddressed clinical requirements. Monoclonal antibody therapies are procedures that employ laboratory-engineered antibodies specifically produced to target certain antigens on cancer cells, thereby promoting a more effective immune system response. For example, in September 2024, Pfizer Inc., a biotech and pharma corporation based in the US, shared optimistic results from the Phase II clinical inspection of ponsegromab, a monoclonal antibody that specifically targets Growth/Differentiation Factor 15 (GDF-15). The promising study results present a potential new remedy for those suffering from the debilitating condition, for which few effective treatments are available today. The findings from the Phase 2 trial point to a significant advancement in managing the underlying inflammation leading to muscle degradation and weight loss in cancer patients. This treatment strategy seeks not only to enhance physical performance but also to bolster overall life quality of cancer patients, signifying a significant milestone in cancer care.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125
Which geographic areas are influencing the growth of the cancer anorexia-cachexia syndrome (cacs) market?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Typhoid Vi Polysaccharide Vaccine Global Market Report 2025
Conjugate Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Hepatitis B Virus (HBV) Global Market Report 2025
https://thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
